Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae

December 2017

Meropenem/vaborbactam (Vabomere, VAY-boh-meer) will be the first antibiotic to combine a carbapenem with a beta-lactamase inhibitor.

Adding the beta-lactamase inhibitor vaborbactam helps meropenem outsmart carbapenem-resistant superbugs, which cause about 9,000 infections in the U.S. each year.

Meropenem/vaborbactam is approved to treat complicated urinary tract infections (UTIs), including pyelonephritis. Early evidence suggests it's also effective for bacteremia, pneumonia, and intra-abdominal infections.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote